Compare Stocks: ARCT, OMER, SNDX, and DMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$9.84	$13.55	$5.50 ▼ $17.96	$279.65M	2.48	638,036 shs	474,929 shs
DMRA Damora Therapeutics, Inc. Common Stock	$21.09	$24.48	$4.95 ▼ $38.33	$1.30B	1.43	472,657 shs	359,783 shs
OMER Omeros	$16.57	$18.55	$6.24 ▼ $21.24	$1.20B	2.57	1.10 million shs	698,891 shs
SNDX Syndax Pharmaceuticals	$13.40	$17.82	$12.80 ▼ $25.59	$1.19B	0.42	2.46 million shs	4.25 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	-4.84%	-28.95%	+70.83%	-12.30%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	+14.37%	+2.08%	-28.36%	+150.18%
OMER Omeros	0.00%	+2.28%	-17.48%	+46.12%	+119.47%
SNDX Syndax Pharmaceuticals	0.00%	+3.88%	-26.37%	-34.70%	-0.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$9.84	$13.55	$5.50 ▼ $17.96	$279.65M	2.48	638,036 shs	474,929 shs
DMRA Damora Therapeutics, Inc. Common Stock	$21.09	$24.48	$4.95 ▼ $38.33	$1.30B	1.43	472,657 shs	359,783 shs
OMER Omeros	$16.57	$18.55	$6.24 ▼ $21.24	$1.20B	2.57	1.10 million shs	698,891 shs
SNDX Syndax Pharmaceuticals	$13.40	$17.82	$12.80 ▼ $25.59	$1.19B	0.42	2.46 million shs	4.25 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	-4.84%	-28.95%	+70.83%	-12.30%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	+14.37%	+2.08%	-28.36%	+150.18%
OMER Omeros	0.00%	+2.28%	-17.48%	+46.12%	+119.47%
SNDX Syndax Pharmaceuticals	0.00%	+3.88%	-26.37%	-34.70%	-0.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.90	Moderate Buy	$22.29	126.48% Upside
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	120.48% Upside
OMER Omeros	2.60	Moderate Buy	$30.33	83.06% Upside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$41.80	211.94% Upside

Current Analyst Ratings Breakdown

Latest ARCT, OMER, SNDX, and DMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	ARCT Arcturus Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/19/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/15/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$22.00
10/13/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$38.00
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/8/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/2/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/1/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/29/2026	SNDX Syndax Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$35.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	3.41	N/A	N/A	$7.53 per share	1.31
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
OMER Omeros	N/A	N/A	$1.87 per share	8.85	($1.71) per share	N/A
SNDX Syndax Pharmaceuticals	$172.35M	6.89	N/A	N/A	$0.74 per share	18.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
OMER Omeros	-$3.35M	$1.28	6.07	13.69	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)

Latest ARCT, OMER, SNDX, and DMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	OMER Omeros	$0.03	N/A	N/A	N/A	$37.28 million	N/A
11/9/2026	Q3 2026	ARCT Arcturus Therapeutics	-$0.6866	N/A	N/A	N/A	$8.00 million	N/A
11/2/2026	Q3 2026	SNDX Syndax Pharmaceuticals	-$0.4848	N/A	N/A	N/A	$81.91 million	N/A
8/12/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
OMER Omeros	N/A	1.95	1.94
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
OMER Omeros	48.79%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
OMER Omeros	10.50%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
OMER Omeros	175	72.39 million	64.79 million	Optionable
SNDX Syndax Pharmaceuticals	298	88.61 million	84.36 million	Optionable

ARCT, OMER, SNDX, and DMRA Headlines

Recent News About These Companies

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

October 17, 2026 | businesswire.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year Low - Time to Sell?

October 16, 2026 | marketbeat.com

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

October 16, 2026 | uk.finance.yahoo.com

Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List

October 15, 2026 | globenewswire.com

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

October 14, 2026 | zacks.com

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

October 13, 2026 | prnewswire.com

Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says

October 13, 2026 | marketscreener.comM

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Here's What Happened

October 13, 2026 | marketbeat.com

Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright

October 13, 2026 | marketbeat.com

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

October 13, 2026 | benzinga.com

Syndax Pharmaceuticals, Inc. Announces Topline Results From MAXPIRe Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis

October 13, 2026 | marketscreener.comM

Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis

October 13, 2026 | rttnews.com

Syndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge

October 13, 2026 | rttnews.com

Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?

October 13, 2026 | finance.yahoo.com

Syndax Says Pulmonary Fibrosis Drug Trial Misses Primary Endpoint

October 12, 2026 | marketscreener.comM

Syndax Stock Drops 15% After Axatilimab Trial Failure

October 12, 2026 | econotimes.com

Syndax says mid-stage trial of lung disease treatment fails main goal, ends development

October 12, 2026 | msn.com

Syndax Pharmaceuticals stock tumbles on failed IPF trial

October 12, 2026 | finance.yahoo.com

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

October 12, 2026 | globenewswire.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 9, 2026 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARCT, OMER, SNDX, and DMRA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$9.84 0.00 (0.00%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$9.83 -0.01 (-0.10%)

As of 10/23/2026 07:30 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$21.09 0.00 (0.00%)

As of 10/23/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Omeros NASDAQ:OMER

$16.57 0.00 (0.00%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$16.80 +0.23 (+1.38%)

As of 10/23/2026 07:36 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Syndax Pharmaceuticals NASDAQ:SNDX

$13.40 0.00 (0.00%)

As of 10/23/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, OMER, SNDX, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, OMER, SNDX, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, OMER, SNDX, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, OMER, SNDX, and DMRA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Omeros NASDAQ:OMER

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, OMER, SNDX, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, OMER, SNDX, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, OMER, SNDX, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, OMER, SNDX, and DMRA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Omeros NASDAQ:OMER

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools